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ABSTRACT
Background  Rituximab inhibited structural damage at 
1 year in patients with rheumatoid arthritis (RA) who had 
had a previous inadequate response to tumour necrosis 
factor (TNF) inhibitors.
Objective  To assess structural damage progression 
through 2 years.
Methods  Intention-to-treat patients with one post-
baseline radiograph (rituximab n=281; placebo n=187) 
received background methotrexate (MTX) and were 
randomised to rituximab (2×1000 mg infusions, 2 weeks 
apart) or placebo; patients were eligible for rituximab 
re-treatment every 6 months. By week 104, 82% of the 
placebo population had received ≥1 dose of rituximab. 
Radiographic end points included the change in total 
Sharp score (TSS), erosion and joint space narrowing 
scores at week 104.
Results  At week 104, signiﬁ  cantly lower changes in 
TSS (1.14 vs 2.81; p<0.0001), erosion score (0.72 vs 
1.80; p<0.0001) and joint space narrowing scores (0.42 
vs 1.00; p<0.0009) were observed with rituximab plus 
MTX vs placebo plus MTX. Within the rituximab group, 
87% who had no progression of joint damage at 1 year 
remained non-progressive at 2 years.
Conclusions  Rituximab plus MTX demonstrated 
signiﬁ  cant and sustained effects on joint damage 
progression in patients with RA and a previously 
inadequate response to TNF inhibitors.
INTRODUCTION
Before the development of targeted biological 
treatments, irreversible joint damage and defor-
mity leading to a progressive decline in functional 
status and increased work disability were common 
  outcomes for patients with rheumatoid arthritis 
(RA).1 2 Biological treatments that inhibit tumour 
necrosis factor α (TNFα), T-cell costimulation or 
interleukin 6 have demonstrated the ability to 
inhibit radiographic progression in patients with 
either early or longstanding disease.3–8
Rituximab, a monoclonal antibody that selectively 
targets CD20-positive B cells, reduces the signs and 
symptoms of RA and has been proved to inhibit joint 
damage progression over 1 year in patients with RA 
for whom TNF inhibitors produced an inadequate 
response.9 10 Here we report the sustained effects of 
rituximab on the progression of joint damage over 
an extended period of 2 years.
PATIENTS AND METHODS
Patients
Patients in this post hoc analysis were participants 
in the phase III REFLEX study.9 Eligibility criteria for 
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REFLEX have been described   previously.9 Brieﬂ  y, 
patients were included if they had active RA despite 
treatment with methotrexate (MTX) ≥10 mg/week 
and had experienced an inadequate response (lack of 
efﬁ  cacy or intolerance) to at least one TNF inhibitor.
The study was performed in accordance with 
the Declaration of Helsinki. All participating sites 
received approval from their governing institu-
tional review board (or equivalent) and all patients 
provided written informed consent.
Study protocol
REFLEX was a randomised, double-blind, placebo-
controlled, phase III study with an option for fur-
ther treatment courses under a separate   extension 
study. Patients continued background MTX and 
were randomly assigned to placebo or rituximab 
(MabThera, Roche, Welwyn Garden City, UK; 
Rituxan, Genentech, South San Francisco, California, 
USA and Biogen Idec, San Diego, California, USA). 
Rituximab 1000 mg was administered by intrave-
nous infusion on days 1 and 15. All patients received 
corticosteroid treatment,   consisting of intravenous 
methylprednisolone 100  mg before each infusion 
and oral prednisone during the 2-week treatment 
period (60 mg on days 2−7, 30 mg on days 8−14).
From weeks 16 to 24, patients who failed to 
respond to treatment could receive rescue therapy. 
Patients randomised to placebo could receive ritux-
imab and patients randomised to rituximab could 
receive standard care. Patients completing week 
24 were eligible to receive further courses of ritux-
imab within an open-label extension study. Further 
courses of rituximab were also available for placebo 
patients who had responded to rescue treatment.
Radiographs of hands, wrists (posterior/anterior) 
and feet (anterior/posterior) were performed at 
screening (baseline) and at weeks 24, 56 and 104, 
relative to randomisation. Radiographs were read 
at a central reading facility by two independent 
expert radiologists and scored using the Genant-
modiﬁ   ed Sharp scoring system.11 12 Radiologists 
were blinded to the treatment group assignment, 
chronological order of the radiographs and patients’ 
clinical response.
Radiographic outcome measures
Radiographic assessments included the mean 
change in total Genant-modiﬁ   ed Sharp score 
(mTSS), the erosion score, the joint space nar-
rowing score and the proportion of patients with 
no   further joint damage progression (deﬁ  ned as a 
change in mTSS ≤0). All assessments compared 
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baseline and week 104. Radiographic changes were also deter-
mined during discrete time intervals of baseline to 24 weeks, 
24–56 weeks and 56–104 weeks. The annualised progression 
rate (APR) was calculated to provide a measure of the rate of 
change in progression standardised to a common time interval. 
The APR for each patient was calculated as follows:
APR 364
Score Score
StudyDay StudyDay
time2 time1
time2 time1
=×
−
−
Statistical analysis
The primary population for the radiographic analysis was 
deﬁ  ned as all patients (including those withdrawing or receiving 
rescue) included in the REFLEX intention-to-treat (ITT) popula-
tion who had at least one post-baseline radiograph (either 24, 
56 or 104 weeks). All missing data were imputed using linear 
extrapolation of the progression observed from baseline to the 
week 24/week 56 radiographs. Analyses were conducted using 
a non-parametric analysis (Van Elteren test), stratiﬁ  ed by region 
(USA vs non-USA) and baseline rheumatoid factor (positive vs 
negative). In addition, sensitivity analyses were conducted using 
observed data only.
RESULTS
Patient characteristics and disposition
A total of 517 patients were randomised: 308 to rituximab plus 
MTX and 209 to placebo plus MTX. Of these, 468 patients (281 
rituximab patients and 187 placebo patients) were included in 
the REFLEX ITT population, and had a baseline ﬁ  lm at screening 
and at least one post-baseline radiograph. A total of 197 ritux-
imab and 135 placebo patients had radiographs at both baseline 
and week 104. The baseline characteristics and measures of dis-
ease activity were similar in both treatment groups and were 
similar to those of the original ITT population (table 1).
By week 104, 165/281 patients (59%) in the rituximab group 
had received two or more courses of rituximab. Of the 187 
patients randomised to placebo, 154 (82%) had received at least 
one dose of rituximab before their last observed radiograph, 
with 94 (50%) having received two or more courses. Only 33 
patients (18%) initially randomised to placebo did not receive 
rituximab treatment.
Radiographic efﬁ  cacy
The mean change in the mTSS from baseline to 104 weeks 
was signiﬁ  cantly lower in the rituximab group than in the pla-
cebo group (1.14 vs 2.81, respectively; p<0.0001). Signiﬁ  cant 
differences in the mean change in erosion and joint space nar-
rowing scores were also observed (ﬁ  gure 1).
The proportion of patients with no progression in joint dam-
age over 2 years was signiﬁ  cantly higher in the rituximab group 
than in the placebo group (57% vs 39%, respectively; p<0.0001; 
ﬁ  gure 2A). Similarly, a higher proportion of patients randomised 
to rituximab had no change in erosion scores over the 2 years 
compared with patients randomised to placebo (60% vs 44%, 
respectively; p=0.0003; ﬁ   gure 2B). Sensitivity analyses using 
observed data were consistent with the primary analyses.
Over discrete time intervals, the rate and extent of progression 
of joint damage in patients randomised to rituximab remained 
consistent. The rituximab group exhibited consistent mean 
changes in the mTSS during the ﬁ  rst and second years, while 
the placebo group—most of whom had by then received ritux-
imab—showed slower rates of change during their second year 
(ﬁ  gure 2C). Similarly, whereas in the rituximab group the APR 
remained consistent, in the placebo group it gradually declined 
from 1.60 points/year during the initial 24-week period to 0.93 
points/year in the second year (ﬁ  gure 2D).
The proportion of patients with no change in their mTSS 
  (ﬁ  gure 2A) and with no new erosions increased during each time 
period in each treatment group (ﬁ  gure 2B). Of those patients 
randomised to rituximab who did not progress during the ﬁ  rst 
year, 87% did not progress during the second year either.
DISCUSSION
Inhibition of structural joint damage by rituximab in patients with 
with RA and a previous inadequate response to TNF inhibitors 
was ﬁ  rst described over a 1-year period.10 Here we have demon-
strated that the initial effects of rituximab are maintained over an 
extended interval of 2 years, with all measures of joint damage 
signiﬁ  cantly improved compared with placebo plus MTX.
Treatment with rituximab was associated with a signiﬁ  cantly 
higher proportion of patients with no progression of joint dam-
age over the 2 years compared with placebo plus MTX. The 
proportion of patients with no progression (57%) achieved with 
rituximab treatment compares well with that seen with other 
Table 1  Baseline demographic characteristics of the patients*
Characteristics
Placebo plus 
MTX (n=187)
Rituximab plus 
MTX (n=281)
Female/male (n (%)) 150 (80)/37 (20) 228 (81)/53 (19)
Age (years) 52.9 (12.1) 52.5 (12.2)
Disease duration (years) 11.7 (7.7) 11.9 (8.2)
Swollen joint count 23.1 (12.8) 23.2 (11.9)
Tender joint count 33.2 (15.7) 33.2 (15.1)
CRP (mg/dl) 3.7 (3.8) 3.7 (3.9)
Anti-CCP positive (n (%)) 82 (44) 130 (46)
ESR (mm/h) 48.7 (26.5) 47.8 (25.6)
HAQ-DI score 1.9 (0.54) 1.8 (0.57)
Total Genant–modiﬁ  ed Sharp score 32.5 (31.5) 30.6 (26.7)
*Except where indicated otherwise values are the mean (SD).
CCP, cyclic citrullinated peptide; CRP, C-reactive protein; ESR, erythrocyte sedimentation 
rate; HAQ-DI, Health Assessment Questionnaire-Disability Index; MTX, methotrexate.
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Figure 1  Changes from baseline to 2 years in total Genant–modiﬁ  ed 
Sharp, erosion and joint space narrowing (JSN) scores in patients 
treated with rituximab (2 × 1000 mg) plus methotrexate (MTX) or 
placebo plus MTX *p<0.005; **p<0.0001 versus placebo plus MTX.
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treatments with biological agents, albeit in less treatment-refrac-
tory patient populations.6 13 14 Importantly, of those rituximab 
patients with no progression in the ﬁ  rst year, 87% maintained a 
non-progressive status during the second year.
Although patients were initially randomised to either ritux-
imab or placebo, 82% of placebo patients had switched to 
rituximab by 2 years. The impact of this switch on the progres-
sion of joint damage in this placebo–rituximab group is evident 
by the reduced changes in scores between time periods and the 
gradual slowing in their APR. The consequence of this switch 
to active treatment is that the degree of progression observed 
in the ‘placebo’ group is less than would have been observed 
had those patients been maintained solely on MTX, thereby 
underestimating the relative treatment effect. The extent of 
this discrepancy can be estimated using the method devised by 
Strand and Sharp15 for estimating APRs. By dividing the base-
line mean mTSS (32.5) by the mean disease duration (11.7), 
the predicted progression for the placebo group over 2 years 
was 5.55. However, the observed progression was much lower 
(2.81), suggesting that the switch to rituximab had a large 
inﬂ  uence on the progression of joint damage in this control 
group. Consequently, the relative treatment effect size cannot 
be accurately measured. Nevertheless, using the predicted and 
observed progression in the placebo group a reduction in joint 
damage of 59–79% for rituximab plus MTX compared with 
placebo plus MTX could be estimated. Given the estimated 
nature of this effect, together with the lack of available radio-
graphic data in similar patient populations, comparisons of this 
effect size with other biological agents used for RA would not 
be appropriate.
In conclusion, this 2-year analysis demonstrates that ritux-
imab plus MTX has signiﬁ  cant and sustained effects on the inhi-
bition of joint damage in a population of patients with active 
RA who had previously experienced an inadequate response to 
TNF inhibitors.
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